GSK Gobbles Up Sirtris For $720 Million, But Still Prefers Alliances To Big Buys

GlaxoSmithKline's $720 million acquisition of the Cambridge, Mass.-based biotech Sirtris reflects an exception to, not the rule of, the U.K. drug manufacturer's deal-making strategy, according to company executives